Dose Comparison Study of Menactra® in US Children

Inclusion Criteria : * Aged 2 to \< 11 years on the day of inclusion. * Provision of assent form signed by the subject (depending on age) and informed consent form signed by the parent(s) or another legally acceptable representative. * Subject and parent/legal guardian able to attend all scheduled visits and comply with all trial procedures. Exclusion Criteria : * Previous vaccination against meningococcal disease with either the trial vaccine or another vaccine. * Participation in the active (i.e., treatment) portion of another clinical trial investigating a vaccine, drug, medical device, or a medical procedure in the 4 weeks preceding the first trial vaccination. * Planned participation in another clinical trial during the present trial period. * Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic corticosteroids therapy. * Suspected or known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to a product containing any of the substances present in the study vaccine . * Chronic illness at a stage that could interfere with trial conduct or completion, in the opinion of the Investigator. * Receipt of blood or blood-derived products in the past 3 months. * Received any vaccine (other than desensitization therapy for allergies or influenza vaccine within 2 weeks before vaccination) in the 4 weeks preceding the first trial vaccination. * Planned receipt of any vaccine within the 4 weeks following any trial vaccination(s). * Known human immunodeficiency virus (HIV), hepatitis B surface antigen (HBs antigen), or hepatitis C seropositivity. * History of invasive meningococcal infection (confirmed either clinically, serologically, or microbiologically). * Thrombocytopenia, coagulation disorder, or anticoagulant use in the 3 weeks preceding inclusion contraindicating intramuscular (IM) vaccination. * Anticipated to receive oral or injected antibiotic therapy within the 72 hours prior to any of the trial blood draws. * Personal or family history of Guillain-Barré Syndrome (GBS). * Any condition which, in the opinion of the Investigator, would pose a health risk to the subject or interfere with the evaluation of the vaccine.